Search research articles

Search research articles

Related Experiment Videos

Optimal antimicrobial therapy for sepsis.

Douglas N Fish¹

¹Department of Pharmacy Practice, School of Pharmacy, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Campus Box C-238, Denver, CO 80262, USA. doug.fish@uchsc.edu

American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists

|March 12, 2002

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Oral Cephalexin Population Pharmacokinetics and Target Attainment Analysis in Infants 7-60 Days Old.

Journal of the Pediatric Infectious Diseases Society·2025

Same author

Evaluation of Oral Amoxicillin/Clavulanate for Urinary Tract Infections Caused by Ceftriaxone Non-Susceptible Enterobacterales.

Pharmacy (Basel, Switzerland)·2024

Same author

Cefadroxil and cephalexin pharmacokinetics and pharmacodynamics in children with musculoskeletal infections.

Antimicrobial agents and chemotherapy·2024

Same author

Oritavancin as sequential therapy for Gram-positive bloodstream infections.

BMC infectious diseases·2024

Same author

Cefepime Extraction by Extracorporeal Life Support Circuits.

The journal of extra-corporeal technology·2023

Same author

Real-World Use of Tedizolid Phosphate for 28 Days or More: A Case Series Describing Tolerability and Clinical Success.

Open forum infectious diseases·2022

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Choosing the right antimicrobial therapy for sepsis is crucial. Early, broad-spectrum treatment targeting likely pathogens, considering local resistance, improves patient outcomes.

Area of Science:

Infectious Diseases
Critical Care Medicine
Pharmacology

Background:

Sepsis management hinges on timely and appropriate antimicrobial selection.
Historically linked to Gram-negative bacteria, sepsis is increasingly caused by Gram-positive pathogens, associated with higher mortality.
Common sepsis pathogens include Enterobacteriaceae, Pseudomonas aeruginosa, and Staphylococcus aureus.

Purpose of the Study:

To discuss the principles guiding the selection of antimicrobial therapy for sepsis.
To highlight the importance of prompt initiation of effective antimicrobial treatment.
To review common pathogens and current recommendations for empirical sepsis therapy.

Main Methods:

Literature review and synthesis of current guidelines and evidence regarding antimicrobial therapy for sepsis.

Related Experiment Videos

Analysis of factors influencing antimicrobial selection: source of infection, local susceptibility patterns, and host factors.

Evaluation of recommended empirical regimens, including broad-spectrum agents and combination therapy.

Main Results:

Antimicrobial choice depends on infection source, common pathogens, local resistance, and patient factors.
Prompt initiation of therapy is critical for survival.
Gram-positive pathogens are frequent causes of sepsis and high mortality.
Empirical therapy should be broad-spectrum, targeting likely pathogens, with antipseudomonal beta-lactams +/- aminoglycosides often recommended.
Routine vancomycin and antifungal use is discouraged unless clinically indicated.

Conclusions:

Optimal antimicrobial therapy selection for sepsis requires a multifaceted approach.
Prompt, broad-spectrum empirical treatment, guided by local epidemiology and host factors, is essential.
Further clinical studies are needed to define optimal sepsis treatment strategies, particularly regarding monotherapy versus combination therapy.